PPARγ is the master regulator of glucose metabolism.15-keto-PGE2 is  an endogenous PPARγ ligand whitch is degraded by ZADH1. We found that increasing 15-keto-PGE2  promotes glucose uptake. We identified several ZADH1 inhibitors which could increase 15-keto-PGE2 promote glucose uptake via activating  PPARγ. Our results showed that inhibition of ZADH1 is a novel approach to  treat type 2 diabes mell

The widely used ant-diabetic agent, thiazolidinedione (TZD) lower glucose by activating PPARγ. However, TZD has significant side effects including weight gain, water retention,osteoporosis. We found that 15-keto-PGE2 is an endogenous PPARγ ligand. Inhibiting ZADH1, the degradating enzyme of   15-keto-PGE2, could increase 15-keto-PGE2promote glucose uptakeis a novel strategy for treating diabetes

Diabetes mellitus is a global epidemic disease. TZD is widely used to treat diabetes mellitus. However, it is associated with several adverse side effects. The development of ZADH1 small molecule inhibitor is a novel therapeutic strategy for treating diabetes without the side effect of TZD.